Skip to main content
Log in

Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer

  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Current approaches to the treatment of cancer (radiation and chemotherapy) are limited by the toxicity to normal tissues and the sensitivity of tumor cells to these treatments. The use of gene delivery vector systems for the introduction of genetic elements into normal and neoplastic tissues which code for proteins that protect the normal chemotherapy-sensitive tissues and sensitize the tumor cells to radiation and chemotherapy, may contribute to an overall improvement in the outcome of cancer treatment programs. This chapter will review the clinical trials either completed or about to be initiated which are designed to accomplish these goals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

About this article

Cite this article

Fujii, T., Fu, S.Q., Yin, L.H. et al. Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer. Breast Cancer 4, 210–212 (1997). https://doi.org/10.1007/BF02966508

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966508

Keywords

Navigation